Nicox Submits NDA To FDA For NCX 470 In Treating Ocular Hypertension; Response Expected In 2027

Nicox SA (via U.S. licensee Kowa) submitted an NDA to the U.S. FDA for NCX 470 for open-angle glaucoma and ocular hypertension. The filing is a positive regulatory milestone, but no efficacy, timeline, or FDA decision date was provided in the announcement.

Analysis

Nicox SA (via U.S. licensee Kowa) submitted an NDA to the U.S. FDA for NCX 470 for open-angle glaucoma and ocular hypertension. The filing is a positive regulatory milestone, but no efficacy, timeline, or FDA decision date was provided in the announcement.